NervGen Pharma Stock Rises Following Positive Study Results
Why Is NervGen Pharma Stock Gaining Tuesday?
Benzinga
Image: Benzinga
NervGen Pharma Corp. (NASDAQ:NGEN) shares increased after the company reported positive results from its Phase 1b/2a CONNECT SCI study, showing its candidate NVG-291 significantly improved gait quality in chronic spinal cord injury patients. The stock was up 5.29% in premarket trading.
- 01NervGen Pharma's NVG-291 showed a statistically significant gait improvement (p=0.0197) in spinal cord injury patients.
- 02100% of the treated subjects were classified as responders compared to only 10% in the placebo group (p=0.0001).
- 03The company plans to advance NVG-291 into a Phase 3 RESTORE study for chronic tetraplegia, set to begin in mid-2026.
- 04Currently, NGEN stock is trading 40.8% below its 20-day SMA of $3.65, indicating potential overhead resistance.
- 05The stock is trading 9.3% above its 200-day SMA of $1.98, suggesting a critical support level.
Advertisement
In-Article Ad
NervGen Pharma Corp. (NASDAQ:NGEN) experienced a stock increase of 5.29% during premarket trading on Tuesday, following the announcement of positive results from its Phase 1b/2a CONNECT SCI study. The Vancouver-based biopharmaceutical company reported that its lead candidate, NVG-291, demonstrated a statistically significant improvement in gait quality for patients with chronic spinal cord injuries, as evidenced by an independent analysis conducted by Newton Tech. Notably, all ten treated subjects were classified as responders, compared to just one in the placebo group, highlighting the potential efficacy of NVG-291. NervGen's CEO, Adam Rogers, emphasized that these results bolster the company's plans to progress into a Phase 3 RESTORE study, anticipated to commence in mid-2026. Despite the positive momentum, NGEN stock remains significantly below its short-term moving averages, with key resistance at $3.65 and support at $1.98, indicating critical levels for investors to monitor as the stock navigates its recovery.
Advertisement
In-Article Ad
The positive study results could enhance investor confidence, potentially leading to increased funding for further research and development.
Advertisement
In-Article Ad
Reader Poll
What do you think about the future of NervGen Pharma's NVG-291?
Connecting to poll...
Read the original article
Visit the source for the complete story.



